BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21613233)

  • 1. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.
    Chen M; Gong L; Qi X; Xing G; Luan Y; Wu Y; Xiao Y; Yao J; Li Y; Xue X; Pan G; Ren J
    Toxicol Sci; 2011 Aug; 122(2):288-96. PubMed ID: 21613233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
    Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
    Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dicoumarol inhibits rat NAD(P)H:quinone oxidoreductase in vitro and induces its expression in vivo.
    Stiborova M; Levova K; Barta F; Dracinska H; Sulc M; Hodek P; Frei E; Arlt VM; Schmeiser HH
    Neuro Endocrinol Lett; 2014; 35 Suppl 2():123-32. PubMed ID: 25638376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
    Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
    Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
    Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
    Bárta F; Levová K; Frei E; Schmeiser HH; Arlt VM; Stiborová M
    Mutat Res Genet Toxicol Environ Mutagen; 2014 Jul; 768():1-7. PubMed ID: 24769487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
    Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
    Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
    Stiborova M; Frei E; Arlt VM; Schmeiser HH
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases.
    Stiborová M; Mareš J; Frei E; Arlt VM; Martínek V; Schmeiser HH
    Environ Mol Mutagen; 2011 Jul; 52(6):448-59. PubMed ID: 21370283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I.
    Levova K; Moserova M; Nebert DW; Phillips DH; Frei E; Schmeiser HH; Arlt VM; Stiborova M
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):360-7. PubMed ID: 22982977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
    Sborchia M; De Prez EG; Antoine MH; Bienfait L; Indra R; Valbuena G; Phillips DH; Nortier JL; Stiborová M; Keun HC; Arlt VM
    Arch Toxicol; 2019 Nov; 93(11):3345-3366. PubMed ID: 31602497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury.
    Xue X; Xiao Y; Zhu H; Wang H; Liu Y; Xie T; Ren J
    Nephrol Dial Transplant; 2008 Oct; 23(10):3074-81. PubMed ID: 18495746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
    Stiborová M; Martínek V; Frei E; Arlt VM; Schmeiser HH
    Curr Drug Metab; 2013 Jul; 14(6):695-705. PubMed ID: 23701164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skullcapflavone II, a novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver and kidney injury in mice.
    Dong YP; Chen SZ; He HS; Sun ZR; Jiang LX; Gu YQ; Zhang Y; Feng F; Chen C; Fan ZC; Chen XF; Wen W; Wang HY
    Acta Pharmacol Sin; 2023 Jul; 44(7):1429-1441. PubMed ID: 36697978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid.
    Stiborová M; Frei E; Arlt VM; Schmeiser HH
    Xenobiotica; 2014 Jan; 44(2):135-45. PubMed ID: 24152141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes.
    Chang MM; Lin CN; Fang CC; Chen M; Liang PI; Li WM; Yeh BW; Cheng HC; Huang BM; Wu WJ; Chen YA
    Sci Rep; 2018 May; 8(1):6960. PubMed ID: 29725048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
    Wu J; Liu X; Fan J; Chen W; Wang J; Zeng Y; Feng X; Yu X; Yang X
    Toxicology; 2014 Apr; 318():22-31. PubMed ID: 24530882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
    Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
    Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
    Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.